Clinical Outcome of Nosocomial Pneumonia following Imipenem/Cilastatin Therapy
- 1 March 1987
- journal article
- research article
- Published by SAGE Publications in Drug Intelligence & Clinical Pharmacy
- Vol. 21 (3) , 272-276
- https://doi.org/10.1177/106002808702100308
Abstract
Eighteen patients in a neurosurgery intensive care unit who had nosocomial pneumonia and/or bacteremia were treated with imipenem/cilastatin. The 16 patients who were evaluable had pneumonia; 4 of these had concurrent bacteremia. Eleven patients had a satisfactory clinical response (69 percent) and all patients with positive blood cultures had the organism eradicated. There were 44 organisms isolated from the initial culture of bronchial secretion and 32 of these organisms were gram-negative bacilli (72.5 percent). One patient with pneumonia who initially had Pseudomonas aeruginosa sensitive to imipenem developed resistance during therapy. Adverse effects were minimal; one case of nausea occurred, which was thought to be related to a short infusion time. The most prominent laboratory abnormality was an increase in platelet count, seen in 50 percent of treated patients.Keywords
This publication has 21 references indexed in Scilit:
- Inducible β-lactamases and non-hydrolytic resistance mechanismsJournal of Antimicrobial Chemotherapy, 1984
- Emergence of Resistance During Therapy with the Newer -Lactam Antibiotics: Role of Inducible -Lactamases and Implications for the FutureClinical Infectious Diseases, 1983
- Novel Resistance Selected by the New Expanded-Spectrum Cephalosporins: A ConcernThe Journal of Infectious Diseases, 1983
- Urinary Recovery of N -Formimidoyl Thienamycin (MK0787) as Affected by Coadministration of N -Formimidoyl Thienamycin Dehydropeptidase InhibitorsAntimicrobial Agents and Chemotherapy, 1983
- Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humansAntimicrobial Agents and Chemotherapy, 1983
- Thienamycin: development of imipenem-cilastatinJournal of Antimicrobial Chemotherapy, 1983
- In vitro Activity and β-Lactamase Stability of N-Formimidoyl Thienamycin Compared to that of Second and Third Generation CephalosporinsChemotherapy, 1982
- Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strainsAntimicrobial Agents and Chemotherapy, 1980
- MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activitiesAntimicrobial Agents and Chemotherapy, 1980
- Structure and absolute configuration of thienamycinJournal of the American Chemical Society, 1978